Impact of calcitriol and an AKT inhibitor, AT7867, on survival of rat C6 glioma cells

References

• Tan AC, Ashley DM, Lopez GY, et al. Management of glioblastoma: state of the art and future directions. CA A Cancer J Clin. 2020;70(4):299–312.
   PubMed Web of Science ®Google Scholar
• Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297.
   PubMed Web of Science ®Google Scholar
• Delgado-Lopez PD, Saiz-Lopez P, Gargini R, et al. A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know. Clin Transl Oncol. 2020;22(11):1909–1922.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Hess KR, Liu L, et al. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. 2005;7(4):485–494.
   PubMed Web of Science ®Google Scholar
• Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):1–14.
   Google Scholar
• Gallagher JC, Bikle DD. Vitamin D: mechanisms of action and clinical applications. Endocrinol Metab Clin North Am. 2017;46(4):xvii–xviii.
   PubMed Web of Science ®Google Scholar
• Campbell FC, Xu H, El-Tanani M, et al. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol. 2010;79(1):1–9.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Murray A, Synnott NC, et al. Vitamin D analogues: potential use in cancer treatment. Crit Rev Oncol Hematol. 2017;112:190–197.
   PubMed Web of Science ®Google Scholar
• Cataldi S, Arcuri C, Lazzarini A, et al. Effect of 1α,25(OH)2 Vitamin D3 in mutant P53 glioblastoma cells: involvement of neutral sphingomyelinase1. Cancers (Basel). 2020;12(11):3163.
   PubMed Web of Science ®Google Scholar
• Bak DH, Kang SH, Choi DR, et al. Autophagy enhancement contributes to the synergistic effect of vitamin D in temozolomide-based glioblastoma chemotherapy. Exp Ther Med. 2016;11(6):2153–2162.
   PubMed Web of Science ®Google Scholar
• Naveilhan P, Berger F, Haddad K, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors?J Neurosci Res. 1994;37(2):271–277.
   PubMed Web of Science ®Google Scholar
• Hu P, Li S, Tian N, et al. Acidosis enhances the self-renewal and mitochondrial respiration of stem cell-like glioma cells through CYP24A1-mediated reduction of vitamin D. Cell Death Dis. 2019;10(1):25.
   PubMedGoogle Scholar
• Bikle DD. Vitamin D: newer concepts of its metabolism and function at the basic and clinical level. J Endocr Soc. 2020;4(2):bvz038.
   PubMed Web of Science ®Google Scholar
• Xu Y, He B, Pan Y, et al. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol. 2014;35(5):4153–4169.
   PubMedGoogle Scholar
• Elmaci I, Ozpinar A, Ozpinar A, et al. From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. Metab Brain Dis. 2019;34(3):687–704.
   PubMed Web of Science ®Google Scholar
• Norlin M. Effects of vitamin D in the nervous system: Special focus on interaction with steroid hormone signalling and a possible role in the treatment of brain cancer. J Neuroendocrinol. 2020;32(1):e12799.
   PubMed Web of Science ®Google Scholar
• Sui A, Xu Y, Pan B, et al. Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells. J Cell Physiol. 2019;234(10):17990–17998.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683–2710.
   PubMed Web of Science ®Google Scholar
• Maj E, Trynda J, Maj B, et al. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and VDR polymorphism. J Steroid Biochem Mol Biol. 2019;193:105431.
   PubMed Web of Science ®Google Scholar
• Vanoirbeek E, Krishnan A, Eelen G, et al. The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab. 2011;25(4):593–604.
   PubMed Web of Science ®Google Scholar
• Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–33450.
   PubMedGoogle Scholar
• Zhao HF, Wang J, Shao W, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16(1):100.
   PubMedGoogle Scholar
• Ryskalin Ryskalin L, Gaglione A, Limanaqi F, et al. The autophagy status of cancer stem cells in glioblastoma multiforme: from cancer promotion to therapeutic strategies. IJMS. 2019;20(15):3824.
   Google Scholar
• Proietti S, Cucina A, D’Anselmi F, et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res. 2011;50(2):150–158.
   PubMed Web of Science ®Google Scholar
• Yu WD, Ma Y, Flynn G, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle. 2010;9(15):3022–3029.
   PubMed Web of Science ®Google Scholar
• Bai L, McEachern D, Yang CY, et al. LRIG1 LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. Cancer Res. 2012;72(5):1229–1238.
   PubMed Web of Science ®Google Scholar
• Fabian AK, Marz A, Neimanis S, et al. InterAKTions with FKBPs-mutational and pharmacological exploration. PLoS One. 2013;8(2):e57508.
   PubMed Web of Science ®Google Scholar
• Peng X, Tiwari N, Roy S, et al. Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D3 in human colon cancer cells. J Endocrinol. 2012;212(2):207–215.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Kanterewicz B, Buch S, et al. CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol. 2012;355(1):153–161.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Kanterewicz B, Shoemaker S, et al. Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J Steroid Biochem Mol Biol. 2013;136:264–270.
   PubMed Web of Science ®Google Scholar
• Axanova LS, Chen YQ, McCoy T, et al. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate. 2010;70(15):1658–1671.
   PubMed Web of Science ®Google Scholar
• Kure S, Nosho K, Baba Y, et al. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2765–2772.
   PubMed Web of Science ®Google Scholar
• Grimshaw KM, Hunter LJ, Yap TA, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther. 2010;9(5):1100–1110.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yan HB, Wang J, et al. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget. 2016;7(29):46127–46141.
   PubMedGoogle Scholar
• Zhang S, Deng Z, Yao C, et al. AT7867 inhibits human colorectal cancer cells via AKT-dependent and AKT-independent mechanisms. PLoS One. 2017;12(1):e0169585.
   PubMed Web of Science ®Google Scholar
• Bjune K, Wierod L, Naderi S. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms. PLoS One. 2019;14(6):e0218537.
   PubMed Web of Science ®Google Scholar
• Huang YF, Wu YH, Cheng WF, et al. Vitamin D-binding protein enhances epithelial ovarian cancer progression by regulating the insulin-like growth factor-1/Akt pathway and vitamin D receptor transcription. Clin Cancer Res. 2018;24(13):3217–3228.
   PubMed Web of Science ®Google Scholar
• Matsunawa M, Akagi D, Uno S, et al. Vitamin D receptor activation enhances benzo[a]pyrene metabolism via CYP1A1 expression in macrophages. Drug Metab Dispos. 2012;40(11):2059–2066.
   PubMed Web of Science ®Google Scholar
• Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55(1):13–31.
   PubMed Web of Science ®Google Scholar
• Hu N, Zhang H. CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells. Exp Ther Med. 2018;16(4):2821–2830.
   PubMed Web of Science ®Google Scholar
• Zhdanov DD, Fahmi T, Wang X, et al. Regulation of apoptotic endonucleases by EndoG. DNA Cell Biol. 2015;34(5):316–326.
   PubMed Web of Science ®Google Scholar
• Minchenko OH, Tsymbal DO, Minchenko DO, et al. Hypoxic regulation of the expression of cell proliferation related genes in U87 glioma cells upon inhibition of ire1 signaling enzyme. Ukr Biochem J. 2016;88(1):11–21.
   PubMedGoogle Scholar
• Waye S, Naeem A, Choudhry MU, et al. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging (Albany, NY). 2015;7(10):854–868.
   PubMedGoogle Scholar
• Kunapuli P, Kasyapa CS, Hawthorn L, et al. LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem. 2004;279(22):23151–23157.
   PubMed Web of Science ®Google Scholar
• Choi DH, Kim EM, Son HJ, et al. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem. 2008;106(1):405–415.
   PubMed Web of Science ®Google Scholar
• Poole AT, Sitko CA, Le C, et al. Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells. J Enzyme Inhib Med Chem. 2020;35(1):672–681.
   PubMed Web of Science ®Google Scholar